FG-3246 for advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of prostate adenocarcinoma (a common type of prostate cancer) confirmed by a biopsy.
- Your cancer must have spread to other parts of the body (metastatic) and be resistant to hormone therapy (castration-resistant).
- You must have had no more than one prior treatment with a second-generation hormone therapy (like abiraterone or enzalutamide).
- You must have a tumor sample available (either from a recent biopsy or an old one) for testing.
- You must not have had chemotherapy before, except for one type called taxane-based chemo if it was more than 12 months ago.
- You must not have a gene mutation (like BRCA1) that has an approved targeted therapy available, unless you can't get that therapy or you refuse it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
This early-phase trial tests a new oral drug, GT-220F, for men whose prostate cancer has spread and no longer responds to hormone therapy. It may be especially for patients whose cancer has specific genetic changes in the PTEN or PIK3CB genes.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests a new cancer-fighting drug called AZD2265 against standard treatment for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. You may qualify if your cancer previously responded to PSMA-targeted radiation treatments but is now growing again.
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.